Abstracts
- 09/01/2012 - V. A. Huynh-Thu
- 09/01/2012 - R. Küffner
- 09/01/2012 - C. Ambroise
- 16/09/2011 - M. Bunster
- 27/04/2011 - P. Meyer
- 06/04/2011 - D. Débois
- 30/03/2011 - J. Wouters
- 28/01/2011 - J.-C. Lambert
- 13/12/2010 - J. Giard
- 17/11/2010 - B. Charloteaux
- 12/05/2010 - P. Soumillion
- 30/04/2010 - J.-P. Vert
- 14/04/2010 - X. Tordoir
- 24/03/2010 - J.C. Voegel
- 17/03/2010 - A. Turtoi
- 24/02/2010 - L. Palmeira
- 27/01/2010 - D. Devos
- 09/12/2009 - F. Heuze
- 25/11/2009 - L. Geris
- 19/11/2009 - V. Gabelica
- 14/10/2009 - G. Zocchi
- 30/09/2009 - K. Van Steen
- 12/06/2009 - D. Gianola
- 05/06/2009 - F. J. Theis
- 02/06/2009 - M. Babu
- 07/05/2009 - J. Eyzaguirre
- 22/04/2009 - E. Bullinger
- 08/04/2009 - F. Francis
- 04/03/2009 - Kick-off
Genetics of Alzheimer’s disease
Jean-Charles Lambert
Date and place: Friday January, 28th 3:00 pm at E50 (B35)
Recent advances and future Alzheimer's disease (AD) is the prime cause of dementia and presents a strong genetic predisposition (60 to 80% of the attributable risk).In addition to APOE -a major recognized genetic determinant of AD-, systematic, high-throughput genomic approaches have recently allowed the characterization of four new genetic determinants : CLU, CR1, PICALM and BIN1.
Even if the complete picture of AD genetics is still not fully understood, the characterization of these new AD genetic determinants is likely going to strongly modify our perception of the pathophysiological process involved in AD. Furthermore, in the next few years, we are likely to identify an almost exhaustive list of the genes involved in AD susceptibility. Finally, the advent of high-throughput sequencing will allow to gain a detailed understanding of the link between these genetic determinants and the AD process thanks to the characterisation of functional variants.